Two decades of pegfilgrastim: what have we learned? Where do we go from here?

References

• Gould Rothberg BE, Quest TE, Yeung SJ, et al. Oncologic emergencies and urgencies: a comprehensive review. CA Cancer J Clin. 2022;72(6):570–593.
   PubMed Web of Science ®Google Scholar
• Keng MK, Sekeres MA. Febrile neutropenia in hematologic malignancies. Curr Hematol Malig Rep. 2013;8(4):370–378.
   PubMed Web of Science ®Google Scholar
• Cantwell L, Perkins J. Infectious disease emergencies in oncology patients. Emerg Med Clin North Am. 2018;36(4):795–810.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524–4531.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475–2484.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Tomita D, et al. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res Treat. 2013;139(3):863–872.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Rolston KV. How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract. 2010;6(3):149–152.
   PubMedGoogle Scholar
• Aagaard T, Reekie J, Jorgensen M, et al. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. Cancer Med. 2020;9(9):3033–3042.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116(23):5555–5563.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–2266.
   PubMed Web of Science ®Google Scholar
• Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med. 2011;2(5):859–866.
   PubMed Web of Science ®Google Scholar
• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916–1924.
   PubMed Web of Science ®Google Scholar
• Saxena A, Rubens M, Ramamoorthy V, et al. Hospitalization rates for complications due to systemic therapy in the United States. Sci Rep. 2021;11(1):7385.
   PubMed Web of Science ®Google Scholar
• Tai E, Guy GP, Dunbar A, et al. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552–e561.
   PubMed Web of Science ®Google Scholar
• Averin A, Silvia A, Lamerato L, et al. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Support Care Cancer. 2021;29(4):2179–2186.
   PubMed Web of Science ®Google Scholar
• Dulisse B, Li X, Gayle JA, et al. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ. 2013;16(6):720–735.
   PubMedGoogle Scholar
• Schenfeld JR, Bennett CW, Li S, et al. Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017. J Oncol Pharm Pract. 2021;27(1):128–142.
   PubMed Web of Science ®Google Scholar
• Li S, Liu J, Guo H, et al. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015. Support Care Cancer. 2020;28(6):2637–2649.
   PubMed Web of Science ®Google Scholar
• Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008;6(2):109–118.
   PubMedGoogle Scholar
• Nordvig J, Aagaard T, Daugaard G, et al. Febrile neutropenia and long-term risk of infection among patients treated with chemotherapy for malignant diseases. Open Forum Infect Dis. 2018;5(10):ofy255.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Djulbegovic B, Norris LB, et al. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013;368(12):1131–1139.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328–340.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2015;33(28):3199–3212.
   PubMed Web of Science ®Google Scholar
• Chan A, Wong QX, Ali MK, et al. Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia. Support Care Cancer. 2014;22(4):1105–1112.
   PubMed Web of Science ®Google Scholar
• Lee S, Knox A, Zeng IS, et al. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer. 2013;21(3):841–846.
   PubMed Web of Science ®Google Scholar
• Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007;147(6):400–411.
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Tzivelekis S, et al. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer. 2017;25(2):439–447.
   PubMed Web of Science ®Google Scholar
• Shaw J, Schenfeld J, Balasubramanian A, et al. Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN). J Clin Oncol. 2021;39(28_suppl):314.
   Web of Science ®Google Scholar
• Lyman GH, Yau L, Nakov R, et al. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol. 2018;29(9):1903–1910.
   PubMed Web of Science ®Google Scholar
• Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3):196–205.
   PubMedGoogle Scholar
• Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28(17):2914–2924.
   PubMed Web of Science ®Google Scholar
• Stefanski HE, Bo-Subait S, Kobusingye H, et al. Comparable incidence rates of hematologic and non-hematologic malignancies, thrombotic events, and autoimmune disorders in unrelated adult donors undergoing bone marrow collection versus peripheral blood stem cell mobilization with recombinant human granulocyte colony-stimulating factor (rHuG-CSF): results of the donor long-term follow-up study by the national marrow donor program (NMDP). Blood. 2022;140(Supplement 1):10862–10864.
   Web of Science ®Google Scholar
• Aapro M, Boccia R, Leonard R, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017;25(11):3295–3304.
   PubMed Web of Science ®Google Scholar
• Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13(6):903–909.
   PubMed Web of Science ®Google Scholar
• Burris HA, Belani CP, Kaufman PA, et al. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract. 2010;6(3):133–140.
   PubMedGoogle Scholar
• Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11(1):404.
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Barron R, et al. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol. 2012;35(3):267–274.
   PubMed Web of Science ®Google Scholar
• Mahtani R, Crawford J, Rifkin R, et al. Abstract PS9-50: a multicenter, prospective, observational study to determine the incidence of febrile neutropenia (FN), persistence and G-CSF utilization among cancer patients at high risk for FN receiving pegfilgrastim by an on-body injector (OBI) versus other FN prophylaxis strategies: an interim analysis. Cancer Res. 2021;81(4_Supplement):PS9–50.
   Web of Science ®Google Scholar
• Rifkin RM, Crawford J, Mahtani RL, et al. A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices. Support Care Cancer. 2022;30(10):7913–7922.
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Weycker D, Bensink M, et al. Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. Curr Med Res Opin. 2020;36(3):483–495.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Wilde ET, Wright JD, et al. Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol. 2012;30(8):806–812.
   PubMed Web of Science ®Google Scholar
• Weycker D, Bensink M, Lonshteyn A, et al. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment. Curr Med Res Opin. 2019;35(6):1073–1080.
   PubMed Web of Science ®Google Scholar
• Gerlier L, Lamotte M, Awada A, et al. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin’s lymphoma. BMC Cancer. 2010;10:642.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–3167.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm. 2007;13(4):337–348.
   PubMed Web of Science ®Google Scholar
• Biron P, Ray-Coquard I, Le Cesne A, et al. ELYPSE 2: a prospective randomized trial comparing filgrastim (G-CSF) in primary and secondary prophylaxis in patients (pts) at high risk for febrile neutropenia (FN). J Clin Oncol. 2006;24(18_suppl):8614.
   Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178–1184.
   PubMed Web of Science ®Google Scholar
• Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986;232(4746):61–65.
   PubMed Web of Science ®Google Scholar
• Curran MP, Goa KL. Pegfilgrastim. Drugs. 2002;62(8):1207–1213.
   PubMed Web of Science ®Google Scholar
• Willis F, Pettengell R. Pegfilgrastim. Expert Opin Biol Ther. 2002;2(8):985–992.
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325(3):164–170.
   PubMed Web of Science ®Google Scholar
• Crawford J, Glaspy JA, Stoller RG, et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005;3(1):36–46.
   PubMedGoogle Scholar
• Biganzoli L, Untch M, Skacel T, et al. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol. 2004;31(3 Suppl 8):27–34.
   PubMed Web of Science ®Google Scholar
• FDA. NEULASTA® (pegfilgrastim) injection, for subcutaneous use 2002. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125031s180lbl.pdf
   Google Scholar
• Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10(11):1235–1244.
   PubMed Web of Science ®Google Scholar
• Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18(13):2522–2528.
   PubMed Web of Science ®Google Scholar
• Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;50(5):295–306.
   PubMed Web of Science ®Google Scholar
• Lyman GH. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin Biol Ther. 2005;5(12):1635–1646.
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35.
   PubMed Web of Science ®Google Scholar
• Tan H, Tomic K, Hurley D, et al. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin. 2011;27(1):79–86.
   PubMed Web of Science ®Google Scholar
• Becker PS, Griffiths EA, Alwan LM, et al. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Comprehen Cancer Network. 2020;18(1):12–22.
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Neulasta Prescribing Information 2020. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/neulasta/neulasta_pi_hcp_english.pdf
   Google Scholar
• Li Y, Klippel Z, Shih X, et al. Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy. Cancer Chemother Pharmacol. 2016;77(4):703–712.
   PubMed Web of Science ®Google Scholar
• NCCN. Hematopoietic growth factors version 1.2023: NCCN; 2022. https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf
   Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205.
   PubMed Web of Science ®Google Scholar
• Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24(19):2991–2997.
   PubMed Web of Science ®Google Scholar
• Gawade PL, Li S, Henry D, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer. 2020;28(9):4413–4424.
   PubMed Web of Science ®Google Scholar
• Zullo AR, Lou U, Cabral SE, et al. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia. J Oncol Pharm Pract. 2019;25(6):1357–1365.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hillner BE. A way forward on the medically appropriate use of white cell growth factors. J Clin Oncol. 2012;30(14):1584–1587.
   PubMed Web of Science ®Google Scholar
• Adams JR, Lyman GH, Djubegovic B, et al. G-CSF as prophylaxis of febrile neutropenia in SCLC. Expert Opin Pharmacother. 2002;3(9):1273–1281.
   PubMedGoogle Scholar
• Link H, Nietsch J, Kerkmann M, et al. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy–a representative sample survey in Germany. Support Care Cancer. 2016;24(1):367–376.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2008;2008(4):CD003189.
   PubMed Web of Science ®Google Scholar
• Marion S, Tzivelekis S, Darden C, et al. Same-Day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale. Support Care Cancer. 2016;24(9):3889–3896.
   PubMed Web of Science ®Google Scholar
• Stephens JM, Bensink M, Bowers C, et al. Travel burden associated with granulocyte colony-stimulating factor administration in a medicare aged population: a geospatial analysis. Curr Med Res Opin. 2018;34(8):1351–1360.
   PubMed Web of Science ®Google Scholar
• Patel J, Rainess RA, Benfield MJ, et al. Retrospective analysis of clinical outcomes associated with the use of pegfilgrastim on-body injector in patients receiving chemotherapy requiring granulocyte colony-stimulating factor support. Hosp Pharm. 2021;56(2):77–80.
   PubMed Web of Science ®Google Scholar
• Neulasta®. (pegfilgrastim) Onpro® kit: healthcare provider instructions for use. 2022. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Neulasta/neulasta_ifu_hcp_pt_english.pdf
   Google Scholar
• Ziextenzo® Prescribing Information: FDA. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761045lbl.pdf
   Google Scholar
• Harbeck N, Wang J, Otto GP, et al. Safety analysis of proposed pegfilgrastim biosimilar in phase I and phase III studies. Future Oncol. 2019;15(12):1313–1322.
   PubMed Web of Science ®Google Scholar
• Waller CF, Ranganna GM, Pennella EJ, et al. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia. Ann Hematol. 2019;98(5):1217–1224.
   PubMed Web of Science ®Google Scholar
• Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American society of clinical oncology growth factors expert panel. J Clin Oncol. 2000;18(20):3558–3585.
   PubMed Web of Science ®Google Scholar
• Siena S, Piccart MJ, Holmes FA, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003;10(3):715–724.
   PubMed Web of Science ®Google Scholar
• Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23(9):2283–2295.
   PubMed Web of Science ®Google Scholar
• Wang L, Baser O, Kutikova L, et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2015;23(11):3131–3140.
   PubMed Web of Science ®Google Scholar
• Drugs.com. Neulasta sales data 2014. https://www.drugs.com/stats/neulasta
   Google Scholar
• Crawford J, Moore DC, Morrison VA, et al. Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: a review of adherence to present guidelines for usage. Cancer Treat Res Commun. 2021;29:100466.
   PubMedGoogle Scholar
• Weycker D, Barron R, Edelsberg J, et al. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat. 2012;133(1):301–310.
   PubMed Web of Science ®Google Scholar
• Ozer H. The timing of chemotherapy-induced neutropenia and its clinical and economic impact. Oncology (Williston Park). 2006;20(5 Suppl 4):11–15.
   PubMedGoogle Scholar
• McBride A, Alrawashdh N, Bartels T, et al. Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy. Future Oncol. 2021;17(26):3485–3497.
   PubMed Web of Science ®Google Scholar
• Moore L, Bartels T, Persky DO, et al. Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience. Support Care Cancer. 2021;29(8):4867–4874.
   PubMed Web of Science ®Google Scholar
• Eckstrom J, Bartels T, Abraham I, et al. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI. Support Care Cancer. 2019;27(3):873–878.
   PubMed Web of Science ®Google Scholar
• Leiva M, Pennisi A, Harnden KK, et al. The feasibility of same day pegfilgrastim-cbqv administration in breast cancer patients receiving myelosuppressive chemotherapy regimens at a northern Virginia cancer center. J Clin Oncol. 2021;39(15_suppl):e18687.
   Web of Science ®Google Scholar
• Kitchen K, Mosier MC. Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy. Future Oncol. 2022;18(23):2551–2560.
   PubMed Web of Science ®Google Scholar
• Alrawashdh N, Vraney J, Choi BM, et al. Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer. Future Oncol. 2022;18(19):2381–2390.
   PubMed Web of Science ®Google Scholar
• Ma X, Kang J, Li Y, et al. Pegfilgrastim safety and efficacy on the last chemotherapy day versus the next: systematic review and meta-analysis. BMJ Support Palliat Care. 2021;bmjspcare-2020-002532.
   PubMed Web of Science ®Google Scholar
• NEULASTA®. (pegfilgrastim) injection, for subcutaneous use 2002. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125031s180lbl.pdf
   Google Scholar
• Tice J, Bloudek L, McKenna A, et al. Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects; Revised Scoping Document. Institute for Clinical and Economic Review. 2022. https://icer.org/wp-content/uploads/2021/08/ICER_Neutropenia_Revised_Scope_092221.pdf
   Google Scholar
• Yang BB, Morrow PK, Wu X, et al. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer Chemother Pharmacol. 2015;75(6):1199–1206.
   PubMed Web of Science ®Google Scholar
• Kirin K. Kyowa Kirin announces launch of “G-Lasta® subcutaneous injection 3.6 mg BodyPod” in Japan. 2022. https://www.kyowakirin.com/media_center/news_releases/2022/pdf/e20221206_03.pdf
   Google Scholar
• Center For Drug Evaluation and Research FDA. Approval package for Neulasta, injection for subcutaneous use. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125031Orig1s180.pdf
   Google Scholar
• EMA. Neulasta: European Medicines Agency; 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/neulasta
   Google Scholar
• Mahtani RL, Belani R, Crawford J, et al. A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis. Support Care Cancer. 2022;30(7):6135–6144.
   PubMed Web of Science ®Google Scholar
• Chan A, McGregor S, Liang W. Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: an analysis of 1655 patients. Breast. 2014;23(5):676–682.
   PubMed Web of Science ®Google Scholar
• Maahs L, Tang A, Saheli ZA, et al. Real-world effectiveness of the pegfilgrastim on-body injector in preventing severe neutropenia. J Oncol Pharm Pract. 2022;28(1):17–23.
   PubMed Web of Science ®Google Scholar
• Metz M, Semsek D, Rogmans G, et al. Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients. Support Care Cancer. 2021;29(11):6633–6643.
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN Hematopoietic Growth Factors: Short-Term Recommendations Specific to Issues with COVID-19 (SARS-CoV-2): NCCN; 2020. https://www.iononline.com/-/media/assets/ion/pdf/covid19-resources/nccn_hgf_covid-19_19may20.pdf?la=en&hash=9FB98741E9E83D354F8FEFF66AC5F5188E139471
   Google Scholar
• Isidori A, de Leval L, Gergis U, et al. Management of patients with hematologic malignancies during the covid-19 pandemic: practical considerations and lessons to be learned. Front Oncol. 2020;10:1439.
   PubMed Web of Science ®Google Scholar
• Patel R, Saif MW. Pancreatic cancer during covid-19 pandemic: to treat or not to treat? JOP. 2020;21(2):27–28.
   PubMed Web of Science ®Google Scholar
• Yucel A, Skalicky A, Eseyin OR, et al. Development and content validation of the Satisfaction and Experience Questionnaire for Granulocyte Colony-Stimulating factor (SEQ-G-CSF). J Patient Rep Outcomes. 2021;5(1):10.
   PubMedGoogle Scholar
• Saif MW, Hackenyos DW, Smith MH, et al. Racial differences in accepting pegfilgrastim onpro kit (on-body injector) use among cancer patients. Clin Oncol (Las Vegas). 2019;1(6):1026.
   PubMedGoogle Scholar
• Joshi RS, Egbuna OI, Cairns AS, et al. Performance of the pegfilgrastim on-body injector as studied with placebo buffer in healthy volunteers. Curr Med Res Opin. 2017;33(2):379–384.
   PubMed Web of Science ®Google Scholar
• Townley C, Porter C, McMullen N. Comparing grade 4 neutropenia associated with pegfilgrastim administered via the Onprodevice versus manual injection with a prefilled syringe. Hematol Oncol Pharm. 2018;8(3):6.
   Google Scholar
• Sandschafer D, Choi A, Lewis S, et al. MT17 assessment of device failures and medication errors with the pegfilgrastim on-body injector in the US and EU. Value Health. 2022;25(7):S535.
   Web of Science ®Google Scholar
• McBride A, Campbell K, Li E, et al. Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis. J Manag Care Spec Pharm. 2021;27(9):1230–1238.
   PubMed Web of Science ®Google Scholar
• McBride A, Krendyukov A, Mathieson N, et al. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. J Med Econ. 2020;23(1):28–36.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371–2381.
   PubMed Web of Science ®Google Scholar
• Barnes G, Pathak A, Schwartzberg L. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med. 2014;3(6):1477–1484.
   PubMed Web of Science ®Google Scholar